Abstract
Medicines in the cancer therapeutic area account for the third largest source
of revenue within the pharma industry. The cancer market has experienced
significant innovative change in recent years, creating attractive
opportunities for a range of new and established biotechnology players as well
as established pharma companies. Although new product development continues to
involve substantial levels of risk, innovation is the key driving force in the
market, and has led to the competitive exclusion of several of the industry' s
traditional competitors. With successful launches now being applied to
multiple indications faster than ever before, subsequent increases in product
sales volumes are rapidly changing the competitive landscape of the cancer
market. The Cancer Market Outlook to 2012 is a new report published by
Business Insights that provides comprehensive coverage of the major markets in
the global cancer area, incorporating a detailed epidemiological analysis of
the nine major indications and key factors impacting their prevalence. Current
leading brands of treatment within each cancer indication are analysed and
eight of the market' s leading players are profiled. With coverage of over 9 %
of the total market for cancer products, this report profiles the factors and
underlying trends that are driving market transformation and identifies the
most promising areas of potential growth. Forecasts for currently marketed and
key pipeline products over the 2 6-12 period are also provided. Discover the
key market trends and growth drivers of the cancer market, assess the
competitive dynamics of leading pharma companies and evaluate the future
prospects of major products with this new report.
View Cart
